Acute Myeloid Leukemia Archives - Hematology Advisor

Over half of patients receiving azacitidine maintenance achieved protocol completion.

SOHO 2022

Azacitidine May Improve Outcomes in a Subset of Patients With AML

By

Jonathan Goodman, MPhil

September 30, 2022

Researchers sought to determine the safety and efficacy of oral azacitidine vs placebo among patients with AML.

doctor reviewing patient chart at hospital bedside

SOHO 2022

Midostaurin Maintenance Improved Survival in FLT3-Mutated Acute Myeloid Leukemia

By

Vicki Moore, PhD

September 29, 2022

Researchers sought to determine the efficacy of midostaurin maintenance therapy in patients with FLT3-mutated acute myeloid leukemia.

Findings that correlate Epstein-Barr virus status and solid tumors could mean that future cancer tre

SOHO 2022

Detection of FLT3-ITD MRD Is Associated With Relapse and Death in AML

By

Andrea S. Blevins Primeau, PhD, MBA

September 29, 2022

Researchers sought to determine whether detection of FLT3 internal tandem duplications would be prognostic of risk of relapse and death in AML.

The FDA has accepted a New Drug Application (NDA) and granted Priority Review for venetoclax for tre

SOHO 2022

Varying Efficacy Seen in Sequencing of Venetoclax and Targeted Therapies for Acute Myeloid Leukemia

By

Vicki Moore, PhD

September 29, 2022

Researchers sought to determine efficacy patterns with different approaches to sequencing of targeted treatments for patients with acute myeloid leukemia.

Leukemia

KMT2A-PTD Linked With Outcomes in Myelodysplastic Syndromes, Acute Myeloid Leukemia by DNA NGS

By

Jonathan Goodman, MPhil

August 30, 2022

Researchers sought to determine the prognostic utility of KMT2A-PTD in patients with MDS and AML.

General Hematology

Outcomes Similar With Haplo-Cord-PBSCT and MSD-PBSCT in Hematologic Cancers

By

Jonathan Goodman, MPhil

August 23, 2022

Researchers sought to determine whether there were differences in outcomes with haplo-cord-PBSCT vs human leukocyte MSD-PBSCT in patients with hematologic malignancies.

Leukemia

Adding Idasanutlin to Cytarabine Does Not Improve OS in the Relapsed, Refractory Setting of Acute Myeloid Leukemia

By

Jonathan Goodman, MPhil

August 16, 2022

Researchers sought to determine whether adding idasanutlin to cytarabine would improve OS in patients with relapsed or refractory acute myeloid leukemia.